An Observational Study to Compare Plateau Antibody Levels of a Recombinant (E.Coli) Human Papillomavirus Nonavalent (Type 6/11/16/18/31/33/45/52/58) Vaccine Versus Gardasil9 in Healthy Females 18-26 Years of Age
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent Xiamen Innovax Biotech (Primary) ; V 503
- Indications Cervical cancer; Condylomata acuminata
- Focus Pharmacodynamics
Most Recent Events
- 05 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 Mar 2025.
- 05 Nov 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 05 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.